Skip to content
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press & Media
  • Contact
Menu
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press & Media
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT

MODERN SLAVERY STATEMENT

We will not tolerate modern slavery in our supply chains or in any part of our business. We are committed to ensuring that there is transparency in our own business and to tackling any modern slavery in our supply chains.

Our Code of Ethics and employment handbook reflect our commitment to ethical business practice and corporate citizenship. We are reviewing the Code of Ethics and other existing policies and procedures relevant to modern slavery and will develop and update these as necessary to reflect our policy commitments. We will ensure consistent messaging of these policies is distributed throughout our business and management at all levels, as well as in our supply chains.

DUE DILIGENCE AND STEPS TAKEN TO ELIMINATE RISKS

The nature and scale of our business is such that the risks of modern slavery are low. We have rigorous employment policies and practices and have no evidence to suspect that modern slavery is present within our supply chain.

Having assessed our supply chain, and given the nature and scale of our business and supply chains, we consider the risk of modern slavery is low. We have updated our procurement process to require suppliers to our UK business to provide information on modern slavery risks.

TRAINING

Employees are trained on an ongoing basis on topics relating to ethics and compliance. We will continue to identify ways to improve employee and supplier awareness of our efforts to eliminate modern slavery from our business and supplier chain, and will continue to keep abreast of information on global risks of modern slavery.

OUR EFFECTIVENESS IN ELIMINATING MODERN SLAVERY

We will periodically review the effectiveness of the measures we take in ensuring that there is no modern slavery in our supply chains, and we will use this to inform the development of our procedures and best practices. This Statement was approved by the Board of Directors of Albert Labs on the 1st of October 2020.

 

accelerated access to safe and effective psychedelic-assisted therapy for patients with urgent, unmet needs.

  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy
Menu
  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press & Media
  • Contact
Menu
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press & Media
  • Contact

© 2021 Albert Labs. All Rights Reserved

Canada – 6996, Merritt Ave, Burnaby, BC, V5J 4R6

United Kingdom – 61 Mosley Street, Manchester, M2 3HZ

  • About
  • Team
  • Clinical Studies
  • Investing
  • Press & Media
  • Contact
Menu
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press & Media
  • Contact
Twitter Linkedin Youtube Envelope
CSE:ABRT
FSE: VB50
CSE:ABRT
FSE: VB50

About Albert Labs

We’re a pharmaceutical focused, natural drug development company using an accelerated regulatory pathway to deliver faster access to novel mental health therapies for patients with unmet needs

Twitter Linkedin Youtube Envelope
Sign Up

By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.

Twitter
Linkedin
Youtube
Envelope

Latest Press Release

Albert Labs Appoints Principal Investigator for Real World Evidence Study for KRN-101

Read more

By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.